The purpose of the present invention is to provide organometallic salt compositions, prepared by the present innovative method, to produce such compositions that are useful as lubricant additives and/or in lubricant additive compositions, to reduce friction and wear, and also have improved solubility, stability and significantly reduced tendency to agglomerate or form sediments.

The purpose of the present invention is to provide organometallic salt compositions, prepared by the present innovative method, to produce such compositions that are useful as lubricant additives and/or in lubricant additive compositions, to reduce friction and wear, and also have improved solubility, stability and significantly reduced tendency to agglomerate or form sediments.

A pyrazole metal complex for absorption of carbon dioxide, a method for preparing the pyrazole metal complex, and a method for absorbing carbon dioxide are provided; wherein the product produced by reacting pyrazole metal complex and carbon dioxide may be transformed into several economically valuable compounds.

A pyrazole metal complex for absorption of carbon dioxide, a method for preparing the pyrazole metal complex, and a method for absorbing carbon dioxide are provided; wherein the product produced by reacting pyrazole metal complex and carbon dioxide may be transformed into several economically valuable compounds.

A coloring composition includes at least one compound S selected from a compound S-1 represented by Formula (1) or a compound S-2 in which the compound S-1 is coordinated to a metal atom, a pigment, a resin, and a solvent

##STR00001##

A coloring composition includes at least one compound S selected from a compound S-1 represented by Formula (1) or a compound S-2 in which the compound S-1 is coordinated to a metal atom, a pigment, a resin, and a solvent

##STR00001##

Disclosed herein are compound embodiments that are useful for treating a variety of diseases, particularly neurological diseases, motor neuron diseases, copper deficiency-related diseases, and/or mitochondrial deficiencies. The compound embodiments described herein also can be used in PET methods. Also disclosed herein are embodiments of methods of making and using the compound embodiments, as well as pharmaceutical formulations comprising the disclosed compound embodiments.

Disclosed herein are compound embodiments that are useful for treating a variety of diseases, particularly neurological diseases, motor neuron diseases, copper deficiency-related diseases, and/or mitochondrial deficiencies. The compound embodiments described herein also can be used in PET methods. Also disclosed herein are embodiments of methods of making and using the compound embodiments, as well as pharmaceutical formulations comprising the disclosed compound embodiments.

An metal organic complex has the following general formula (I): ##STR00001##
Ar.sup.1, selected from at least one of aromatic hydrocarbyl, R.sup.1-substituted aromatic hydrocarbyl, heterocyclic aromatic hydrocarbyl and R.sup.1-substituted heterocyclic aromatic hydrocarbyl; and Ar.sup.2, selected from one of heterocyclic aromatic hydrocarbyl containing N atoms and R.sup.1-substituted heterocyclic aromatic hydrocarbyl containing N atoms; M being a transitional group metal element; L being selected from one of a monodentate neutral ligand, a monodentate anionic ligand, a bidentate neutral ligand and a bidentate anionic ligand; m being any integer ranging from 1 to 3; and n being any integer ranging from 1 to 2.

An metal organic complex has the following general formula (I): ##STR00001##
Ar.sup.1, selected from at least one of aromatic hydrocarbyl, R.sup.1-substituted aromatic hydrocarbyl, heterocyclic aromatic hydrocarbyl and R.sup.1-substituted heterocyclic aromatic hydrocarbyl; and Ar.sup.2, selected from one of heterocyclic aromatic hydrocarbyl containing N atoms and R.sup.1-substituted heterocyclic aromatic hydrocarbyl containing N atoms; M being a transitional group metal element; L being selected from one of a monodentate neutral ligand, a monodentate anionic ligand, a bidentate neutral ligand and a bidentate anionic ligand; m being any integer ranging from 1 to 3; and n being any integer ranging from 1 to 2.